Podcasts about Medical research

It has been 25 years since Bill Clinton announced one of humanity's most important scientific achievements: the first draft of the human genome. At the time, there was a great deal of excitement about the benefits that this new knowledge would bring, with predictions about curing genetic diseases and even cancer. To find out which of them came to pass, and what could be in store over the next two-and-a-half decades, Madeleine Finlay is joined by science editor Ian Sample, and hears from Prof Matthew Hurles, director of the Wellcome Sanger Institute. Help support our independent journalism at theguardian.com/sciencepod

In this week's episode, we'll learn about using AI to assess transplant risk in myelofibrosis. In a step toward personalized medicine, researchers report on a machine learning model that identifies 25% of patients with poor outcomes. After that: preventing priapism in men with sickle cell anemia. A recent phase 2 feasibility study shows high rates of recruitment, retention, and adherence to oral therapies, coupled with a significant reduction in the risk of this difficult complication. Finally, new research indicates that hallmarks of terminal T-cell exhaustion are absent in multiple myeloma, from diagnosis through maintenance therapy. We explore these provocative and counterintuitive findings arising from profiling of blood and marrow samples.Featured Articles:Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosisA controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafilHallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy

Featuring articles on routine cerebral embolic protection for TAVI, and treatments for cirrhosis due to MASH, BRAF V600E metastatic colorectal cancer, and Pompe's disease; a new review article series on medical education; a case report of a woman with dyspnea on exertion; and Perspectives on addressing ultraprocessed foods, on the costs of dismantling DEI, and on a brother's keeper.

While tuberculosis is not a major health issue in New Zealand, worldwide it remains the leading infectious disease killer.   The vaccine against tuberculosis, called BCG, was first developed in France more than 100 years ago using a strain of bacteria that lost its disease-causing ability. Scientists refer to this as a live attenuated vaccine.   On Our Changing World, the Malaghan Institute's Dr Kerry Hilligan explains to Claire Concannon how this old vaccine is teaching researchers new tricks.

In this episode of the Bill Press Pod, Bill discusses the alarming cuts to medical and scientific research imposed by the Trump administration. Over 1,300 NIH research grants and over 150 clinical trials, including those on critical diseases like HIV, cancer, and chronic diseases, have been canceled or delayed. Colette Delawalla, founder of Stand Up for Science, talks about the detrimental impact of these cuts on the U.S.'s global leadership in science and the brain drain of scientists to other countries. Additionally, data reporter Irena Hwang from The New York Times provides insight into the extent and reasons behind these cuts, revealing that keywords linked to DEI initiatives were a significant factor in the grant cancellations. The episode highlights the far-reaching consequences for public health and scientific progress. Gift Link to the New York Times article: bit.ly/44pTQk6Today Bill highlights the work of Collette Delawalla's Stand up for Science organization. More information at StandupforScience.net.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

A Northwestern Medicine clinical trial led by Rod Passman, MD, could improve the way we care for millions of people with atrial fibrillation, but it is facing an unexpected challenge. There has been a pause in federal funding to Northwestern University that could impact this study's progress. While the trial has not been ordered to stop, all National Institutes of Health funding to Northwestern University has been frozen, raising questions about how long this potential life-saving work can go on without a resolution.  

In this week's episode, we'll learn more about social determinants of health that impact access to allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, or AML; use of megakaryocyte growth factor receptor-based stem cell depletion as part of pretransplant conditioning in ex vivo autologous gene therapy; and identification of an eight-protein risk signature as well as a novel single protein biomarker, soluble oncostatin M receptor, for risk stratification in AML.Featured Articles:Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiacMPL-Based Purification and Depletion of Human Hematopoietic Stem Cells: Implications for Pretransplant ConditioningBlood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes

In this final episode of our four-part series on Northwell's global health efforts in Jamaica, host Sandra Lindsay, RN, sits down with Eric Cioe-Peña, MD, vice president of Northwell's Center for Global Health. Dr. Cioe-Peña shares his personal journey into global health and how he honed Northwell's vast, but scattered efforts around the world into one centralized program that is building sustainable partnerships and making a difference that endures. They also discuss Northwell's unique approach to maximizing the impact of philanthropic giving, harnessing the power of countries with large populations in the U.S., like Guyana and Jamaica, and the future of global health. This is part four of our series. Listen to the entire series here.  About Northwell Health Northwell Health is New York State's largest healthcare provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities. Get more expert insights from leading experts in the field — Northwell Newsroom.  Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities.  

Blood editor Dr. Laurie Sehn discusses the topic of "Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets" featuring Drs. Mark Roschewski, Grzegorz Nowakowski, and Neha Mehta-Shah, who each contributed to the articles featured in the review series on high-risk aggressive lymphoma.See the full review series on high risk lymphoma in volume 144, issue 25 of Blood.

Featuring articles on mismatch repair–deficient tumors, generalized myasthenia gravis, HER2-mutant non–small-cell lung cancer, a Corynebacterium diphtheriae outbreak, and hereditary and sporadic papillary kidney cancer; a review article on unruptured intracranial aneurysms; a case report of a man with respiratory failure and shock after kidney transplantation; and Perspectives on medical AI and clinician surveillance, on pathobiology, and on unrest.

Professor Lorimer Moseley is neuroscientist, who specialises in the complexities and mind-boggling nature of pain - what it is, why it exists, how it works and when it can go wrong.For most of us, pain is a fundamental part of being alive, and staying alive and yet none of us will ever experience the exact same pain as someone else, which makes it incredibly difficult to understand.Every day, we stub our toes and burn our tongues. Some of us break bones and suffer from more serious illnesses and conditions.What you feel when your skin is broken or a ligament is torn is there to tell your brain to be careful, that something is wrong and needs to be protected.But what happens when doctors can't find any damage? When the tissues in your hips or the pictures of your brain seem perfectly fine, but still, there is agonising pain that refuses to leave you alone?Lorimer was a physiotherapist who came to this very specific neuroscience after his own experience with chronic pain, following a pretty gruesome sporting injury that by all accounts had been fixed by surgery.He realised that as he was learning more about how changes in the body are detected (like temperature and pressure), and communicated as pain to the brain through the central nervous system, his own chronic pain started to diminish.Since then, Lorimer has published hundreds of papers and several books on the topic, in his pursuit to help people also dig themselves out of the hellish cruelty of chronic pain.Further informationYou can find more resources from Professor Moseley about tackling persistent or chronic pain online at TameTheBeast.orgFind out more about the Conversations Live National Tour on the ABC website.The Executive Producer of Conversations in Nicola Harrison. This episode was produced by Meggie Morris and presented by Richard Fidler. It explores persistent pain, migraine, arthritis, neurology, psychology, distrust of the medical system, pain relief, hypersensitivity to pain, doctors who believe you, chronic conditions, endometriosis.

In this weekend's episode, three segments from this past week's Washington Journal. First, with a federalized national guard and the Marines on the streets of Los Angeles – a conversation with Mary McCord of Georgetown Law about the legal and Constitutional issues surrounding the domestic deployment of the U.S. military. Then, Former NIH Director Dr. Harold Varmus (VARR-muss) discusses how spending cuts to his former agency is impacting the future of federal medical research. And finally we chat with Wall Street Journal trade reporter Gavin Bade on the latest in U.S.-China trade talks Learn more about your ad choices. Visit megaphone.fm/adchoices

Technologists Bill Gates and Sébastien Bubeck discuss the state of generative AI in medicine, how access to “medical intelligence” might help empower people across healthcare, and how AI's accelerating improvements are likely to affect both delivery and discovery.

In part three of our four-part series, From New York to Jamaica: A Healthcare Partnership, host Sandra Lindsay, RN, reunites with the Northwell Health OB/GYN team who traveled to Kingston in September 2024 to provide pro bono fibroid surgeries. Drs. Michael Nimaroff, Monique Jones, Ruqayyah Abdul-Karim, and Dillon Gurciullo share personal reflections on their experiences collaborating with Jamaican healthcare professionals, navigating the challenges of limited resources, the joys of cultural exchange, and the profound impact of providing life-changing care for women who had been waiting years for surgery. Hear how this unique collaboration is strengthening the Jamaican healthcare system and fostering a spirit of partnership and shared learning between Northwell Health and the University Hospital of the West Indies. This episode offers an inside look at the dedication and passion driving this initiative and its potential to create a healthier future for women in Jamaica. This is part three of our series. You can listen to other episodes here.  About Northwell Health Northwell Health is New York State's largest healthcare provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities. Get more expert insights from leading experts in the field — Northwell Newsroom.  Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities.  

In this week's episode, we' ll learn about how TET3 has a key role in GVHD. In mice, a deficiency of Tet3 in donor T cells inhibited pathogenic immunoglobulin class switching and suppressed lung fibrosis. Accordingly, TET3 may be a new therapeutic target in chronic GVHD. After that: rilzabrutinib, a BTK inhibitor for ITP. In a randomized, placebo-controlled trial, treatment produced rapid and durable platelet responses, with acceptable safety, in adults with immune thrombocytopenia who had failed multiple previous therapies. Finally: exploring pre-TCR surface expression patterns in T-cell ALL. Co-inhibition of the interleukin-7 receptor and pre-T cell receptor pathways may play a therapeutic role for a subset of T-lymphoblastic leukemias.Featured Articles: Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHDSafety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 studySurface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL

Featuring articles on treatments for pulmonary fibrosis, for obesity and overweight, for severe hemophilia B, and for a rare genetic disease; a review article on malnutrition in older adults; a case report of a man with a nasopharyngeal mass; a Medicine and Society on John Collins Warren; and Perspectives on undermining women's health research, on addressing antifungal drug resistance, and on conversations that matter in maternal medicine.

In this episode of Clearing the Haze, host Chuck Marting dives into the controversial promotion of psilocybin by Trump's Surgeon General nominee. Through real-world incidents and medical research, he highlights the dangers of casual psilocybin use, including cases of psychosis and long-term disorders like HPPD. Marty also examines global trends, regulatory gaps, and the cultural impact of influencers promoting psychedelics without emphasizing the risks. The discussion calls for stricter regulations, public awareness, and accountability to ensure safety in the face of rising psilocybin normalization. 00:00 Introduction and Episode Overview00:06 Trump's Surgeon General Nominee and Psilocybin02:17 The Dangers of Psychedelics: Real-World Incidents04:29 Medical Research and HPPD08:34 Global Perspective on Psilocybin Use10:31 Cultural Influence and Media Narratives13:54 Policy Recommendations and ConclusionJoseph David Emerson, 44—a seasoned aviator with over 20 years of flying under his belt. Sounds normal until you hear what happened nextapnews.com+8en.wikipedia.org+8theguardian.com+8washingtonpost.com+3en.wikipedia.org+3opb.org+3. Miracle or grit, the on-duty crew subdued him within 30 seconds. Passengers and crew were stunned—but alive abcnews.go.com+2opb.org+2washingtonpost.com+2. en.wikipedia.org+6theguardian.com+6people.com+6

In this special episode, Dr. Shaji Kumar from the Mayo Clinic speaks with Blood editor Dr. Laurie Sehn on a paper recently published in Blood, "Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma". The findings demonstrate eliminating the need for sequential confirmation of response in multiple myeloma. The study, involving 583 episodes of progression, found that simultaneous confirmation of disease progression using two different markers (e.g., serum protein electrophoresis and serum free light chain assay) was 98% accurate, compared to 82% for sequential confirmation. This suggests that simultaneous confirmation could improve clinical trial accuracy and reduce false censoring. The International Myeloma Working Group is set to revise its response criteria to incorporate these findings, potentially simplifying disease assessment and reducing the need for multiple blood draws.

Professor Gita Mishra has been awarded an Order of Australia (AO) in the 2025 King's Birthday Honours List, in recognition of her significant contributions to the field of science.

Dr Jayashri Kulkarni on her Indian-Australian upbringing and her groundbreaking research into women's hormones and mental health (R)Jayashri Kulkarni's family moved from India to Australia in 1961.They found there were no Indian grocery stores, few spices of any kind, and plain yoghurt wasn't available.But the Kulkarnis adapted to their new home, teaching their neighbours how to cook Indian food, and encouraging Jayashri's love for studying.Jayashri became a doctor, and during her training as a psychiatrist she became fascinated by the relationship between women's hormones and mental health.She's since been at the frontline of groundbreaking research, which challenged many of her colleagues and ended up helping women all over the world.Further informationFirst broadcast in February 2024.Find out more about the Conversations Live National Tour on the ABC website.Conversations' Executive Producer is Nicola Harrison. This episode was produced by Tamar Cranswick and presented by Sarah Kanowski.It explores female health, medical research, menopause, perimenopause, hormonal health, female medical research, migration, studying medicine, depression, anxiety, gut health, why don't doctors listen to women, gender stereotypes, underrepresentation in medical research, gaslighting in women's health, women's pain, motherhood, stress, psychiatry, reproductive health, hormonal birth control.

In this How I Treat Series episode Dr. Thomas Ortel leads a discussion with author Dr. Patrick Foy on his paper “How I diagnose and treat thrombocytopenia in geriatric patients”. See the full How I Treat series on geriatric hematology in volume 143 issue 3 of Blood Journal.

In this week's episode, we'll learn more about the identification and characterization of stem cell-like leukemia blasts using single cell multi-omics, cyclophosphamide as a treatment for non-immune effector cell-associated neurotoxicity in patients treated with B-cell maturation antigen, or BCMA, targeted CAR T-cell therapies, and how differences in glycosylation affect the clearance of human plasma-derived and recombinant von Willebrand factor concentrates.Featured Articles:Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcomeCyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatmentEnhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF

Featuring articles on metabolic dysfunction–associated steatohepatitis, lung nodules, breast cancer, and improving birth outcomes; a review article on hemoglobinopathies; a Clinical Problem-Solving on from where it stems; and Perspectives on U.S. research leadership at a crossroads, on health care in an evolving immigration landscape, and on carrying hope while facing a crisis.

Amar Kelkar is a physician at the Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.H. Kelkar. U.S. Research Leadership at a Crossroads — The Impact of Reducing NIH Indirect-Cost Coverage. N Engl J Med 2025;392:2081-2084.

Fibroids are incredibly common. Anywhere from 40% to 80% of people with a uterus will develop this growth, which is benign but can bring severe symptoms like pain, heavy bleeding, and reproductive issues. These symptoms can be not only physically debilitating but also cause emotional and social issues. During a trip to her home country of Jamaica in September 2024, host Sandra Lindsay, RN, interviewed three women whose lives have been deeply impacted by uterine fibroids for years. With the country facing a large backlog in this type of surgery, these women, like so many more, were unable to get surgery, which is why Sandra organized a team of OB/GYNs to travel with her to Jamaica to treat these women at no cost. In this episode, you'll hear their stories and learn more about Northwell's collaborative efforts to provide pro bono fibroid surgeries in Jamaica. This is episode two in a four-part series documenting Northwell's partnership with Jamaica's Ministry of Health to improve women's health on the island. Listen to Episode 1 and Episode 2, available in our feed now.  About Northwell Health Northwell Health is New York State's largest healthcare provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities. Get more expert insights from leading experts in the field — Northwell Newsroom.  Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities.    

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Professor Tye-Din from the Immunology Division, Walter and Eliza Hall Institute of Medical Research, and Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia, on the paper "Purified oat protein can trigger acute symptoms linked to immune activation in coeliac disease patients but not histological deterioration" published in paper copy in Gut in June 2025. Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://spoti.fi/3Ifxq9p).

In the first episode of a special daily series during the 2025 ASCO Annual Meeting, Dr. John Sweetenham discusses the results of 2 studies on the treatment of advanced colorectal cancer plus an additional study exploring the association of Medicaid expansion with cancer survival outcomes. Transcript Dr. John Sweetenham: Hello, and welcome to our special coverage of the 2025 ASCO Annual Meeting on the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'll be bringing you brief analysis on selected abstracts from each day of the Meeting. My disclosures are available in the transcript of this episode.  Today, I'll be reviewing three abstracts, the first two of which address the treatment of advanced colorectal cancer. Today's first study is Abstract 3501. These data were presented by Dr. Heinz-Josef Lenz from the USC Norris Comprehensive Cancer Center and report on the expanded analysis of the CheckMate-8HW trial. This was a phase 3, international, multicenter trial in patients with MSI-high/MMR-deficient metastatic colorectal cancer, who were randomized between nivolumab (nivo) alone, nivolumab plus ipilumomab (ipi) or investigators' choice of chemotherapy (FOLFOX or FOLFIRI) with or without bevacizumab or cetuximab. The study showed that nivo plus ipi demonstrated superior progression-free survival compared with chemotherapy in the first-line setting and superior progression-free survival compared with nivo alone across all lines of therapy. These results led to the approval of nivo + ipi in the first-line setting in patients with MSI-H/dMMR mCRC in the U.S., the EU, and many other countries.  In today's presentation, Dr. Lenz reported on the expanded analyses of nivo plus ipi versus nivo across all lines of therapy and longer follow-up results for nivo and ipi versus chemo in the first-line setting. With longer follow up (the median is now at 47 months) nivo and ipi continued to show progression-free survival benefit compared with chemotherapy with a median PFS of 54.1 months versus 5.9 months, for a hazard ratio of 0.21.  Additionally, the analysis of the effects on PFS2, defined as the time from randomization to progression after subsequent systemic therapy, start of second subsequent systemic therapy, or death, showed that compared with chemotherapy, first-line nivo and ipi was associated with a 72% reduction in the risk of death or disease progression, despite the fact that 71% of those who progressed following chemotherapy crossed over to receive subsequent immunotherapy. The study also showed that across all lines, nivo and ipi demonstrated superior progression-free survival compared with nivo alone, the median not reached versus 39.3 months, for a hazard ratio of 0.62. No new toxicity signals emerged after further analysis. Most treatment-related adverse events with possible immune etiology were observed within the first six months of therapy. The results for PFS2 are particularly significant. Up to now, there has been some reluctance to use nivo and ipi as first-line therapy, partly because of its toxicity profile and based on the rationale that it would be active after other frontline therapies. The observation in this study that the beneficial effects of nivo and ipi are maintained downstream is compelling. The results suggest that delaying the use of this combination to the second line or later may compromise subsequent PFS and supports the use of nivo and ipi as a standard-of-care frontline option for MSI-H/dMMR metastatic colorectal cancer. Moving on, the next study I'm featuring today is Abstract 3503, presented by Dr. Jeanne Tie from the Peter MacCallum Cancer Centre and the Walter and Eliza Hall Medical Institute of Medical Research from Melbourne, Australia. This study reported the impact of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy escalation in stage III colon cancer, focused on the primary analysis of the ctDNA-positive cohort from the randomized DYNAMIC-III trial. As background, about 30% of patients with stage III colon cancer will recur following standard-of-care adjuvant therapy with oxaliplatin-based regimens. And current data show that for those patients with high-risk disease, 6 months of chemotherapy is associated with a lower recurrence rate than 3 months. Circulating tumor DNA following initial surgery has been shown to be a strong independent prognostic factor for these patients, but questions remain about how ctDNA can be used for adaptation of treatment. Questions regarding treatment adaptation were addressed in the DYNAMIC-III trials – specifically, does treatment escalation benefit those who are ctDNA positive following surgery, and can therapy be de-escalated for those who are ctDNA negative. The first of these 2 questions – treatment escalation in the positive group – is the subject of this report. One thousand and two patients were randomized in this study, between ctDNA-informed therapy (502) or standard management (500). Of those patients included in the intent to treat cohorts, 129 were ctDNA positive in the ctDNA-informed arm compared with 130 in the standard management arm. Various pre-planned treatment escalation protocols were used, depending on the choice of first-line therapy. With a median follow up of 42.2 months, there was no difference in 3-year relapse free survival between the ctDNA informed group (48%) and the standard management group (52%). There was, however, a highly significant difference in relapse-free survival for patients who cleared ctDNA by the end of treatment compared with those who didn't. The authors concluded that the recurrence risk for this group remains high, at about 50%, after adjuvant therapy and that it increases with higher ctDNA burden, but treatment escalation didn't appear to reduce the recurrence risk. Clearance of ctDNA was associated with a favorable outcome, suggesting that as more effective treatments are developed in the future for this group, ctDNA will likely prove to have major utility. Changing gears now, my final selection for today is Abstract 11006, presented by Dr. Elizabeth Shafer from the American Cancer Society. This study explored the association of Medicaid expansion with 5-year survival after a cancer diagnosis.  Dr. Schafer began her presentation by providing some historical perspective on the impact of the Affordable Care Act on reducing the number of uninsured adults aged less than 65 years in the United States. She then reviewed some recent data on the impact of Medicaid expansion on cancer care, including improved screening rates, improved access to cancer surgery, and an increase in earlier cancer diagnosis. The current study builds on earlier data from the American Cancer Society which showed improved 2-year overall survival for patients with newly diagnosed cancer following Medicaid expansion. The new study reported by Dr. Schafer examined 5-year cause-specific survival in individuals with cancer since Medicaid expansion, analyzed according to cancer type and various demographic and social factors. Using data from more than 813,000 individuals from 26 states that expanded Medicaid compared with more than 610,000 from 12 states that did not, the authors reported that similar improvements in 5-year cause-specific survival were observed in the expansion and the non-expansion states, but when analyzed by other factors, differences in outcome emerged. For example, although similar improvements in survival between expansion and non-expansion states were seen in urban communities, there was a significant improvement of 2.55 percentage points in survival for individuals in rural communities in expansion states compared with those in non-expansion states. Similar trends were observed in high poverty areas, where improvements in survival were superior in expansion versus non-expansion states.  When examined by cancer type, the authors observed greater improvements in 5-year survival for those with pancreatic, lung, and colorectal cancer, possibly due to improvements in screening and early access to treatment.  The authors concluded that those residing in rural and high-poverty areas experienced the most improvement in cause-specific cancer survival following Medicaid expansion. In summary, it's encouraging to see an improving trend in cancer mortality overall, independent of Medicaid expansion, but it's also important to remember that this is yet another study which confirms how implementation of the ACA has improved cancer outcomes and begun to address some of the disparities in cancer care. Join me again tomorrow to hear more top takeaways from ASCO25. And if you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:  Dr. John Sweetenham    Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose 

In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: venetoclax-based induction therapy in younger patients with AML. Venetoclax plus decitabine was associated with superior safety and non-inferior response rates compared to intensive chemotherapy. Is it time to consider lower-intensity therapy beyond older and unfit patients? Finally, a focus on venous thromboembolism. Researchers link BGAT, an enzyme pivotal to determining blood type, to risk of future VTE. They say high plasma levels of BGAT contribute to risk above and beyond what can be explained by von Willebrand factor and Factor VIII.Featured Articles:One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying themVenetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AMLHisto–blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study

Featuring articles on pulmonary arterial hypertension, oral semaglutide and cardiovascular outcomes, giant-cell arteritis, the loss of subsidized drug coverage and mortality, and neutralizing venom toxins; a review article on cancer of unknown primary site; a case report of a man with fever, nausea, and respiratory failure; and Perspectives on primary care and the free market, federal cuts at the VA, the GINA gap, and the meaning of goodbye.

Doctors in the US have become the first to treat a baby with a customised gene-editing therapy after diagnosing the child with a severe genetic disorder that kills about half of those affected in early infancy. Ian Sample explains to Madeleine Finlay how this new therapy works and how it paves the way for even more complex gene editing techniques. David Liu, a professor at the Broad Institute of MIT and Harvard and the inventor of these therapies, also describes the barriers that could prevent them reaching patients, and how he thinks they can be overcome. Help support our independent journalism at theguardian.com/sciencepod

On this special episode of JHLT: The Podcast, the Digital Media Editors take a look back at the exciting science that was on display at ISHLT2025, the ISHLT 45th Annual Meeting & Scientific Sessions. Topics include: Telomere biology disorders and lung transplantation The meeting's special focus on cardiogenic shock The apixiVAD trial exploring low dose apixaban in HeartMate 3 LVADs Myocardial recovery on durable LVADs For the latest studies from JHLT, visit jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at ishlt.org/jhlt. Full-text abstracts of the meeting can also be found at the JHLT website. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.  

In this week's episode we'll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma.Featured ArticlesClonal Hematopoiesis Landscape in Frequent Blood DonorsIntegrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody responseUpfront Blinatumomab Improves MRD Clearance and Outcome in Adult Ph-negative B-lineage ALL: The GIMEMA LAL2317 Phase 2 Study

In part two of the How I Treat Series on Transfusion Medicine Dr. Erica Wood interviews the "How I Manage Major Hemorrhage" author group: Drs. Jeannie Callium, Keyvan Karkouti, and Ron George.Find the full published review series in Volume 145 Issue 20 of Blood Journal.

Some call it your sixth sense. You refer to it when you have a “gut feeling.” With a vast fiber network running throughout your body, the vagus nerve knows about and helps regulate every critical function in it, from heart rate to digestion to your immune system. Now bioelectric medicine is tapping into that bodily omniscience by using tiny electrical pulses on the vagus nerve to help treat diseases as diverse as epilepsy, diabetes, stroke, Parkinson's, and even depression. In the coming months, the FDA is set to make a decision about a vagus nerve stimulation device, which, if approved, could provide first-of-its-kind treatment for an autoimmune disease that affects millions of Americans. We consider the groundbreaking potential of vagus nerve stimulation and ask whether electricity could one day replace medications. Guest: Kevin Tracey – Neurosurgeon, president of the Feinstein Institutes for Medical Research at Northwell Health, and author of “The Great Nerve: The New Science of the Vagus Nerve and How to Harness Its Healing Reflexes”  Featuring music by Dewey Dellay and Jun Miyake You can get early access to ad-free versions of every episode by joining us on Patreon. Thanks for your support! Big Picture Science is part of the Airwave Media podcast network. Please contact advertising@airwavemedia.com to inquire about advertising on Big Picture Science. Learn more about your ad choices. Visit megaphone.fm/adchoices

Immunologist Dr Michelle Linterman is a Program leader at the Malaghan Institute of Medical Research. 

Today on The Shawn Bolz Show: Bold Shifts in Healthcare & Faith

In this two-part series, Dr. Erica Wood talks with Drs. Masja de Haas, Helen Savoia, and Stella Chou about their articles in the How I Treat Series on Transfusion Medicine. Topics include noninvasive prenatal testing for red blood cell and platelet antigens, transfusion cases in sickle cell disease, and pregnant patients who are alloimmunized to RBC antigens. Find the full published review series in Volume 145 Issue 20 of Blood Journal.

In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differentiation and development of neutropenia. Researchers describe the mechanisms and propose a treatment strategy for restoring granulopoiesis. Finally, ruxolitinib maintenance therapy after allogeneic transplant. In a phase 2 study, this treatment strategy was associated with low rates of chronic graft-versus-host disease. Investigators say the use of JAK inhibitors in this context warrants further study.Featured Articles: Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myelomaA new severe congenital neutropenia syndrome associated with autosomal recessive COPZ1 mutationsLow rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

In medicine, failure can be catastrophic. It can also produce discoveries that save millions of lives. Tales from the front line, the lab, and the I.T. department. SOURCES:Amy Edmondson, professor of leadership management at Harvard Business School.Carole Hemmelgarn, co-founder of Patients for Patient Safety U.S. and director of the Clinical Quality, Safety & Leadership Master's program at Georgetown University.Gary Klein, cognitive psychologist and pioneer in the field of naturalistic decision making.Robert Langer, institute professor and head of the Langer Lab at the Massachusetts Institute of Technology.John Van Reenen, professor at the London School of Economics. RESOURCES:Right Kind of Wrong: The Science of Failing Well, by Amy Edmondson (2023).“Reconsidering the Application of Systems Thinking in Healthcare: The RaDonda Vaught Case,” by Connor Lusk, Elise DeForest, Gabriel Segarra, David M. Neyens, James H. Abernathy III, and Ken Catchpole (British Journal of Anaesthesia, 2022)."Estimates of preventable hospital deaths are too high, new study shows," by Bill Hathaway (Yale News, 2020).“Dispelling the Myth That Organizations Learn From Failure,” by Jeffrey Ray (SSRN, 2016).“A New, Evidence-Based Estimate of Patient Harms Associated With Hospital Care,” by John T. James (Journal of Patient Safety, 2013).To Err is Human: Building a Safer Health System, by the National Academy of Sciences (1999).“Polymers for the Sustained Release of Proteins and Other Macromolecules,” by Robert Langer and Judah Folkman (Nature, 1976).The Innovation and Diffusion Podcast, by John Van Reenen and Ruveyda Gozen. EXTRAS:"The Curious, Brilliant, Vanishing Mr. Feynman," series by Freakonomics Radio (2024).“Will a Covid-19 Vaccine Change the Future of Medical Research?” by Freakonomics Radio (2020).“Bad Medicine, Part 3: Death by Diagnosis,” by Freakonomics Radio (2016).

Featuring articles on multiple sclerosis, narcolepsy type 1, antiretroviral therapy in children with HIV, and porcine kidney xenotransplantation; a review article on Ph-positive acute lymphoblastic leukemia; a case report of a woman with peritonsillar swelling and bleeding; and Perspectives on the power of physicians in dangerous times, on community health centers, on AI-driven clinical documentation, and on driving Jackson.

For a long time the appendix was considered disposable. After all, millions of people have theirs removed each year and go on to live healthy lives. But as Heather F Smith, a professor of anatomy at Midwestern University tells Ian Sample, researchers are increasingly understanding what this small worm-shaped organ may be bringing to the table in terms of our health. Smith explains how the appendix is linked to both our immune system development and gut health, and why she thinks an increasing interest in the microbiome may bring it to greater prominence. Help support our independent journalism at theguardian.com/sciencepod

Pradeep Khosla is the chancellor of UC San Diego and a nationally recognized voice on the evolving role of public research universities. Under his leadership, UC San Diego has doubled in size, broadened its access, and transformed from a "diamond in the rough" into a globally respected powerhouse for innovation, education, and the arts. He spearheaded the expansion of student housing—growing UC San Diego's housing program into the second largest in the nation—to make college more affordable and accessible for thousands. Chancellor Khosla brings a strategic, inclusive lens to higher ed. This Episode:  What should the modern public university look like and who should it serve? In this episode of Stop & Talk, host Grant Oliphant and co-host Crystal Page sit down with Pradeep Khosla, Chancellor of UC San Diego, to discuss the transformational growth and philosophy behind one of the nation's top public universities. Chancellor Khosla offers an expansive view on the role of public research universities in society—from economic impact to cultural integration and educational access. With a focus on abundance over scarcity, Chancellor Khosla explains how UC San Diego has evolved into a national leader in both science and the arts, investing in student housing, public transit access, and downtown engagement. He also reflects on the challenges of leading through federal uncertainty, advocating for research funding, and shaping an inclusive institution that belongs to the community it serves. Key Moments: [3:20] From Pittsburgh to La Jolla – Why Chancellor Khosla came to UC San Diego and what he saw in its untapped potential. [6:05] Elite, Not Elitist – How UC San Diego is challenging the notion that exclusivity equals excellence in higher education. [21:30] Universities as Economic Engines – Why public research institutions are essential to regional prosperity and innovation. [27:30]  Housing is Access – How UCSD is addressing affordability by building one of the largest student housing programs in the country.  [37:40] The Importance of the Arts – The value of connecting the arts to education and community Resources Mentioned in This Episode: UC San Diego Park & Market – A cultural and academic hub in downtown San Diego The Depot – UCSD's newly purchased multidisciplinary arts incubator and cultural hub in Downtown San Diego San Diego Light Rail – Connecting communities to the UCSD campus Take Action: Attend Events at Park & Market: Explore arts, lectures, and public programming in downtown SD. Visit UC San Diego: From the Birch Aquarium to campus cultural events, UCSD is open to all. Support Public Education & Research: Advocate for research funding and equitable higher ed access. Connect with the Arts: Engage with programs at The Depot and La Jolla Playhouse. Explore Philanthropy: Consider supporting educational initiatives that expand opportunity. 

Featuring articles on high-risk smoldering multiple myeloma, M. tuberculosis infection, type 2 diabetes, uncontrolled hypertension, and lymphoma; a review article on the chemistry of food; a case report of a man with weight loss, weakness, and anorexia; and Perspectives on the dismantling of foreign-assistance efforts, on the crushing weight of nonclinical demands in primary care, and on the last dose.

Scientific Sense ® by Gill Eapen: Prof. Kevin Tracey is Professor of Molecular Medicine and Neurosurgery at Hofstra/Northwell. He is also the CEO of Feinstein Institutes for Medical Research. His latest book is Great Nerve. Please subscribe to this channel:https://www.youtube.com/c/ScientificSense?sub_confirmation=1

In this episode of Passing Judgment, host Jessica Levinson speaks with NPR's Elissa Nadworny to unpack the Trump administration's efforts to withhold federal funding from colleges and universities over issues like antisemitism and DEI practices. They discuss how these unprecedented moves are impacting not campus life, but vital medical and scientific research nationwide. Elissa explains the legal challenges schools like Harvard are mounting in response, the stakes involved for the entire higher education sector, and the broader implications for public policy.Here are three key takeaways you don't want to miss:Federal Funding as a Lever in Higher Education Policy: The episode opens by surveying recent actions from the Trump administration regarding federal funding for colleges and universities. The administration is using financial levers—pausing, freezing, or cutting funds—to influence policies on campus, particularly tied to issues like DEI (diversity, equity, and inclusion) and antisemitism. Mechanisms and Legality of Federal Control: The speakers discuss how and why the administration has the power to control this funding. The complexities of federal funding—who controls the purse strings, when Congress vs. the executive branch has authority, and what legal mechanisms are at play—come up. The episode highlights that while presidents can make funding conditional, the legality often hinges on whether proper procedures are followed (Administrative Procedures Act), not just on broad authority.Who Really Loses When Funds Are Cut: The speakers emphasize that federal research dollars are not just about student amenities—they fund major scientific, medical, and technological research. The implications of large-scale cuts ripple well beyond campuses, potentially hurting national health, technological innovation, and local economies (since universities are major employers and research hubs).Follow Our Host: @LevinsonJessica

Direct to consumer tests that claim to tell us our biological – as opposed to chronological – age are getting a lot of attention, but what can they really tell us about our health? Science editor Ian Sample talks to Dr Brian H Chen, an epidemiologist at the California Pacific Medical Center Research Institute, who has conducted research into a variety of these tests called epigenetic clocks. He explains what exactly they are measuring and whether, once we have the results, there are any evidence-based strategies we can adopt to lower our biological age. Help support our independent journalism at theguardian.com/sciencepod

Sponsored by: Set for LifeSet For Life Insurance helps doctors safeguard their future with True Own Occupational Disability Insurance. A single injury or illness can change everything, but the best physicians plan ahead. Protect your income and secure your future before life makes the choice for you. Your career deserves protection—act now at https://www.doctorpodcastnetwork.co/setforlife_______________ In an era where misinformation can masquerade as science, how do you discern credible research? Host Dr. Bradley Block welcomes Dr. Katie Suleta, to unpack the importance of scrutinizing study authors and journals for conflicts of interest. Drawing from her recent experience with the Journal of Personalized Medicine, where a case study on supplements for autism treatment failed to disclose a lead author's affiliation with a supplement company, Dr. Suleta shares her journey to push for its retraction. This episode equips physicians with tools to inoculate themselves against junk science, emphasizing intellectual humility and lateral reading to protect patient care and public trust.Three Actionable Takeaways:Check Author Affiliations – Before reading a study, investigate authors' affiliations and potential conflicts of interest using readily available information to assess bias.Evaluate Journal Credibility – Be wary of journals with overly long or suspicious titles, and research their reputation to avoid predatory publications.Practice Lateral Reading – Cross-check studies or news articles with other sources to verify credibility and understand broader reactions, enhancing your information hygiene.About the Show:PGD  Physician's Guide to Doctoring covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest:Dr. Katie Suleta is a trained epidemiologist with expertise in infectious diseases and health informatics, serving as the regional director of research and graduate medical education. She mentors residents daily and works as a science writer, contributing to outlets like the American Council on Science and Health, The Conversation, Skeptical Inquirer, and STAT News. Known for her advocacy against misinformation, Dr. Saleta recently exposed a case study in the Journal of Personalized Medicine where a lead author's undisclosed supplement company affiliation led her to push for its retraction, highlighting the need for transparency in scientific publishing.LinkedIn: http://linkedin.com/in/katherine-sota-ortecho-447a4899Instagram: https://www.instagram.com/katysota?igsh=Njd0NG4weW90OWJiAbout the Host Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts The Physician's Guide to Doctoring podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance.

Featuring articles on lipoprotein(a), familial polycythemia, leukocyte adhesion deficiency, COPD, and on policies on reducing alcohol consumption; a review article on addressing alcohol use; a Clinical Problem-Solving on gazing into a crystal ball; and Perspectives on death and taxes, on cancer metastases, and on a good innings.

Each year, hundreds of potentially world-changing treatments are discarded because scientists run out of cash. But where big pharma or altruists fear to tread, my friend and I have a solution. It's repugnant, but it will work By Alexander Masters. Read by Tom Andrews. Help support our independent journalism at theguardian.com/longreadpod